MOTS-c vs PT-141
A neutral, side-by-side comparison of two metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
MOTS-c
MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of mitochondrial DNA — not the nuclear genome like most peptides. Under metabolic stress it translocates to the cell nucleus and regulates gene expression tied to insulin sensitivity, fat oxidation, and stress resistance. It is one of the most novel and closely watched compounds in longevity and metabolic research — but it remains preclinical, with no completed human trials of the native peptide.
Full profilePT-141
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts centrally on the nervous system rather than peripherally, distinguishing it mechanistically from PDE5 inhibitors like sildenafil.
Full profile| MOTS-c | PT-141 | |
|---|---|---|
| Category | Metabolic | Metabolic |
| Also known as | Mitochondrial Open Reading Frame of the 12S rRNA type-c, MOTS-c peptide, mitochondrial-derived peptide | Bremelanotide, Vyleesi, Melanocortin receptor agonist |
| Evidence | Preclinical only | FDA-approved |
| Dosing range | 5mg–20mg mg, varies widely (research protocols are extrapolated from rodent data; no validated human regimen exists) | 0.5mg–2mg mg, as needed, 45 minutes before activity (max 1x per 24h) |
| Administration | Subcutaneous injection, Intravenous (research settings) | Subcutaneous injection, Intranasal (historical — discontinued due to BP concerns) |
| Key side effects | Generally well-tolerated in animal studies, Injection site reactions, Theoretical hypoglycemia risk in diabetics or those on insulin sensitizers (AMPK activation), Human safety data are essentially absent — this is an early-stage research compound | Nausea (most common — ~40% in trials), Flushing, Headache, Transient blood pressure elevation |
| Cited sources | 6 references | 1 reference |
Key differences
- Evidence level differs: MOTS-c is preclinical only, while PT-141 is fda-approved.
- Administration: MOTS-c — Subcutaneous injection, Intravenous (research settings); PT-141 — Subcutaneous injection, Intranasal (historical — discontinued due to BP concerns).
- Frequency: MOTS-c is typically varies widely (research protocols are extrapolated from rodent data; no validated human regimen exists); PT-141 is as needed, 45 minutes before activity (max 1x per 24h).
- Research depth: this profile cites 6 sources for MOTS-c vs 1 for PT-141.
How each works
MOTS-c
MOTS-c activates AMPK via the folate–methionine–AICAR pathway and, under metabolic stress, moves into the nucleus to coordinate antioxidant and stress-response gene programs (partly via Nrf2/ARE). In rodent and cell models it reverses high-fat-diet insulin resistance, reduces obesity, and — when injected into aged mice — substantially improves treadmill running capacity, behaving like an 'exercise mimetic.' In humans, exercise raises endogenous MOTS-c, and an East-Asian genetic variant (K14Q) shows mixed associations with longevity and with type 2 diabetes risk. No registered human clinical trials of MOTS-c itself exist; the only human study was of an analog (CB4211), a Phase 1 program that was discontinued.
PT-141
PT-141 activates MC3R and MC4R receptors in the hypothalamus, triggering downstream sexual arousal pathways independent of vascular effects. Phase 3 trials supporting Vyleesi approval showed statistically significant improvements in desire and reductions in distress in women with HSDD. Off-label research explores use in men with erectile dysfunction refractory to PDE5 inhibitors.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.